EUCTR2016-001533-28-Outside-EU/EEA进行中（未招募）1 期
A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,070
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Infants, Children, Adolescents, and Young Adults (<30 year old) with newly diagnosed acute myeloid leukemia (AML).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 1022
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 65
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Major exclusion criteria included juvenile myelomonocytic leukemia, Fanconi's anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone marrow failure syndrome, promyelocytic leukemia (M3), secondary or treatment-related AML; prior chemotherapy, radiation therapy, or any antileukemic therapy; other prior treatment for AML.
研究者
相似试验
进行中（未招募）
1 期
Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels as well as the efficacy of Glasdegib as maintenance after transplantation, in adult patients with Acute Myeloid Leukemia (AML), a tumor characterized from an abnormal proliferation of blood cells present in the bone marrow in the form of immature myeloid precursors, ie cells not yet differentiated, called blasts.Favorable-intermediate-risk Acute Myeloid Leukemia (AML)MedDRA version: 21.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003871-20-ITFONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS414
进行中（未招募）
1 期
Phase II Study on Gemtuzumab Ozogamicin in Combination with All-trans-Retinoic Acid, high-dose Cytarabine and Mitoxantrone in Patients with primary refractory acute myeloid leukemia [GO-A-HAM] - GO-A-HAMEUCTR2004-003739-30-ATniversitätsklinikum Ulm / University Clinical Center Ulm84
已完成
不适用
Phase I study of Gemtuzumab Ozogamicin given in combination with Enocitabine and Daunorubicin as induction therapy for elderly patients with acute myeloid leukemiaacute myeloid leukemiaJPRN-UMIN000002603Japan Adult Leukemia Study Group18
招募中
2 期
Study of the efficacy and safety of gemtuzumab ozogamicin treatment intervention with measurable residual disease as an index for AYA/adult acute myeloid leukemia with t(8;21) and inv(16)JPRN-jRCTs041200063Toshihiro Miyamoto117
已完成
2 期
A study of gemtuzumab ozogamicin in combination with G-CSF after CAG or MEC (CA-G-GO therapy or MEC-G-GO therapy) for relapsed or refractory acute myeloid leukemia.Acute Myeloid LeukemiaJPRN-UMIN000027522Wakayama Medical University20